Page 1430 - Hematology_ Basic Principles and Practice ( PDFDrive )

1276 Part VII Hematologic Malignancies

14. Juliusson G, Heldal D, Hippe E, et al: Subcutaneous injections of 26. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al: Phase II trial of
2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with
Oncol 13:989, 1995. hairy cell leukemia. J Clin Oncol 27:2983, 2009.
15. Saven A, Burian C, Koziol JA, et al: Long-term follow-up of patients 27. Wheaton S, Tallman MS, Hakimian D, et al: Minimal residual disease
with hairy cell leukemia after cladribine treatment. Blood 92:1918, 1998. may predict bone marrow relapse in patients with hairy cell leukemia
16. Goodman GR, Burian C, Koziol JA, et al: Extended follow-up of treated with 2-chlorodeoxyadenosine. Blood 87:1556, 1996.
patients with hairy cell leukemia after treatment with cladribine. J Clin 28. Sausville JE, Salloum RG, Sorbara L, et al: Minimal residual disease
Oncol 21:891, 2003. detection in hairy cell leukemia: Comparison of flow cytometric immu-
17. Chadha P, Rademaker AW, Mendiratta P, et al: Treatment of hairy cell nophenotyping with clonal analysis using consensus primer polymerase
leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of chain reaction for the heavy chain gene. Am J Clin Pathol 119:213, 2003.
the Northwestern University experience. Blood 106:241, 2005. 29. Arons E, Margulies I, Sorbara L, et al: Minimal residual disease in
18. Seymour JF, Kurzrock R, Freireich EJ, et al: 2-chlorodeoxyadenosine hairy cell leukemia patients assessed by clone-specific polymerase chain
+
induces durable remissions and prolonged suppression of CD4 lympho- reaction. Clin Cancer Res 12:2804, 2006.
cyte counts in patients with hairy cell leukemia. Blood 83:2906, 1994. 30. Ravandi F, O’Brien S, Jorgensen J, et al: Phase II study of cladribine fol-
19. Forconi F, Sozzi E, Cencini E, et al: Hairy cell leukemias with unmutated lowed by rituximab in patients with hairy cell leukemia. Blood 118:3818,
IGHV genes define the minor subset refractory to single-agent cladribine 2011.
and with more aggressive behavior. Blood 114:4696, 2009. 31. Else M, Dearden CE, Matutes E, et al: Rituximab with pentostatin or
20. Grever M, Kopecky K, Foucar MK, et al: Randomized comparison of cladribine: an effective combination treatment for hairy cell leukemia
pentostatin versus interferon alfa-2a in previously untreated patients with after disease recurrence. Leuk Lymphoma 52:75, 2011.
hairy cell leukemia: an intergroup study. J Clin Oncol 13:974, 1995. 32. Kreitman R, Wilson W, Calvo KR, et al: Cladribine with immediate
21. Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term follow-up of remis- rituximab for the treatment of patients with variant hairy cell leukemia.
sion duration, mortality, and second malignancies in hairy cell leukemia Clin Cancer Res 19:6873, 2013.
patients treated with pentostatin. Blood 96:2981, 2000. 33. Sivina M, Kreitman R, Arons E, et al: The bruton tyrosine kinase inhibi-
+
22. Arons E, Suntum T, Stetler-Stevenson M, et al: VH4-34 hairy cell tor (PCI-32765) blocks hairy cell leukemia survival, proliferation and
leukemia, a new variant with poor prognosis despite standard therapy. B cell receptor signaling: a new therapeutic approach. Br J Haematol
Blood 114:4687, 2009. 166:177, 2014.
23. Thomas DA, O’Brien S, Bueso-Ramos C, et al: Rituximab in relapsed 34. Pettirossi V, Santi A, Imperi E, et al: BRAF inhibitors reverse the unique
or refractory hairy cell leukemia. Blood 102:3906, 2003. molecular signature and phenotype of hairy cell leukemia and exert
24. Ravandi F, Jorgensen JL, O’Brien SM, et al: Eradication of minimal potent antileukemic activity. Blood 125:1207, 2015.
residual disease in hairy cell leukemia. Blood 107:4658, 2006. 35. Tiacci E1, Park JH, et al: Targeting Mutant BRAF in Relapsed or
25. Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the anti-CD22 Refractory Hairy-Cell Leukemia. N Engl J Med 373(18):1733–1747,
recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell 2015.
leukemia. N Engl J Med 345:241, 2001.